These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Iacobucci I; Lonetti A; Cilloni D; Messa F; Ferrari A; Zuntini R; Ferrari S; Ottaviani E; Arruga F; Paolini S; Papayannidis C; Piccaluga PP; Soverini S; Saglio G; Pane F; Baruzzi A; Vignetti M; Berton G; Vitale A; Chiaretti S; Müschen M; Foà R; Baccarani M; Martinelli G Haematologica; 2008 Dec; 93(12):1814-21. PubMed ID: 18838475 [TBL] [Abstract][Full Text] [Related]
7. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ottmann OG; Pfeifer H Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223 [TBL] [Abstract][Full Text] [Related]
8. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381 [TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
10. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Jones D; Thomas D; Yin CC; O'Brien S; Cortes JE; Jabbour E; Breeden M; Giles FJ; Zhao W; Kantarjian HM Cancer; 2008 Sep; 113(5):985-94. PubMed ID: 18615627 [TBL] [Abstract][Full Text] [Related]
11. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642 [TBL] [Abstract][Full Text] [Related]
12. IK6 isoform with associated cytogenetic and molecular abnormalities in Chinese patients with Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Yao L; Cen J; Chen S; Shen H; Chen Y; He J; Chen Z Leuk Lymphoma; 2013 Aug; 54(8):1626-32. PubMed ID: 23150929 [TBL] [Abstract][Full Text] [Related]
13. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457 [TBL] [Abstract][Full Text] [Related]
15. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Ottmann O; Dombret H; Martinelli G; Simonsson B; Guilhot F; Larson RA; Rege-Cambrin G; Radich J; Hochhaus A; Apanovitch AM; Gollerkeri A; Coutre S Blood; 2007 Oct; 110(7):2309-15. PubMed ID: 17496201 [TBL] [Abstract][Full Text] [Related]
16. Expression of Ikaros isoform 6 in chinese children with acute lymphoblastic leukemia. Zhou F; Mei H; Jin R; Li X; Chen X J Pediatr Hematol Oncol; 2011 Aug; 33(6):429-32. PubMed ID: 21792038 [TBL] [Abstract][Full Text] [Related]
17. In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Kawaguchi H; Taketani T; Hongo T; Park MJ; Koh K; Ida K; Kobayashi M; Takita J; Taki T; Yoshino H; Bessho F; Hayashi Y Leuk Lymphoma; 2005 Feb; 46(2):273-6. PubMed ID: 15621812 [TBL] [Abstract][Full Text] [Related]
18. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361 [TBL] [Abstract][Full Text] [Related]
19. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891 [TBL] [Abstract][Full Text] [Related]
20. Huaier extract enhances the treatment efficacy of imatinib in Ik6 Qu P; Han J; Qiu Y; Yu H; Hao J; Jin R; Zhou F Biomed Pharmacother; 2019 Sep; 117():109071. PubMed ID: 31202171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]